Teva to discontinue mid-stage neurodegenerative disorder study
TEVA•Teva will discontinue its Phase 2 study of emrusolmin in adults with multiple system atrophy after an interim analysis found a low probability of meeting the study’s main goal. Teva said no safety concerns were identified and the decision is not final for the broader emrusolmin program.
1. Study to stop
Teva said it would discontinue the mid-stage study of its experimental oral drug emrusolmin in adults with multiple system atrophy, a rare neurodegenerative disorder. The decision followed an independent data monitoring committee’s recommendation after a planned interim analysis indicated a low probability that the study would meet its main goal if continued.
2. Interim assessment
The trial measured changes in patients’ symptom scores over 48 weeks. Teva said the interim predictive assessment was not the study’s final efficacy analysis and identified no safety concerns. Chief medical officer Eric Hughes said the company was disappointed but remained committed to learning from the data.
3. Program continues
Teva said the discontinuation does not represent a final decision on the broader emrusolmin program, which is being developed with MODAG GmbH. The company plans to share the findings after completing a comprehensive analysis.
